Hepatitis C News

A recent substantial increase in hepatitis C virus infection among reproduction-aged women in the United States highlights a need for routine HCV screening during pregnancy, according to recent data published in Annals Internal Medicine.

Treatment with sofosbuvir and velpatasvir produced a safe, sustained virologic response in patients with HIV who were coinfected with hepatitis C virus, according to findings from a phase 3 study.

AMSTERDAM — All 111 of a cohort of patients in Taiwan coinfected with both hepatitis B and hepatitis C who were treated with Harvoni reached sustained virologic response at 12 weeks, according to data presented at the International Liver Congress.

A state-level evaluation of the burden of hepatitis C virus infection revealed that states in the Western and Southern United States are most impacted by the disease.

In a recent pilot trial, patients who were previously hepatitis C-negative had detectable HCV RNA after transplantation with HCV-infected kidneys. All patients in the trial achieved sustained virologic response with Zepatier.

In a recent editorial, experts discussed the necessity to optimize control and treatment of hepatitis C among patients with substance abuse disorders, to further the goal of HCV elimination.

The Canadian Task Force on Preventive Health Care recommends against screening for hepatitis C virus in low-risk patients, including baby boomers.

AMSTERDAM — Nearly 100% of a cohort of non-cirrhotic patients with HCV who had undergone liver transplantation responded to treatment with glecaprevir/pibrentasvir, according to data presented at the International Liver Congress.

AMSTERDAM — Adherence to treatment and subsequent sustained virologic response were unaffected by drug use in a study of patients enrolled in an opioid agonist treatment program, according to a presenter at the International Liver Congress.

AMSTERDAM — In this exclusive video from International Liver Congress, Andrew Talal, MD, MPH, from the University of Buffalo, New York, discusses alternative paths to ensure patients with substance use disorders with hepatitis C can receive appropriate care.